Provided by Tiger Trade Technology Pte. Ltd.

PAVmed

8.67
-0.2700-3.02%
Post-market: 8.670.00000.00%19:01 EDT
Volume:15.63K
Turnover:136.95K
Market Cap:12.98M
PE:-1.30
High:8.94
Open:8.94
Low:8.51
Close:8.94
52wk High:28.44
52wk Low:6.00
Shares:1.50M
Float Shares:1.20M
Volume Ratio:1.00
T/O Rate:1.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.6481
EPS(LYR):99.15
ROE:17.44%
ROA:-36.78%
PB:1.54
PE(LYR):0.09

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Teledyne, Arm Holdings, Nathan’s Famous

Reuters
·
Jan 21

PAVmed Subsidiary Lucid Diagnostics Wins US Department of Veterans Affairs Contract

MT Newswires Live
·
Jan 21

Why Are PAVmed (PAVM) & Lucid Diagnostics (LUCD) Stocks Up Today?

TIPRANKS
·
Jan 21

BUZZ-Lucid Diagnostics rises after winning VA contract for cancer test

Reuters
·
Jan 21

Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for Esoguard®

THOMSON REUTERS
·
Jan 21

BRIEF-PAVmed Announces Reverse Stock Split

Reuters
·
Dec 30, 2025

PAVmed Announces 1-for-30 Reverse Stock Split

Reuters
·
Dec 30, 2025

PAVmed Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Dec 10, 2025

PAVmed Inc : Ascendiant Capital Markets Cuts Target Price to $17 From $20

THOMSON REUTERS
·
Dec 10, 2025

PAVmed Shareholders Approve Reverse Stock Split and Share Reduction

Reuters
·
Dec 06, 2025

Pavmed Inc. Reports Q3 2025 Earnings and Strategic Focus

TIPRANKS
·
Nov 19, 2025

PAVmed’s Earnings Call: Triumphs and Trials

TIPRANKS
·
Nov 18, 2025

PAVmed Announces Q3 2025 Financial Results and Updates

TIPRANKS
·
Nov 13, 2025

PAVmed reports third quarter 2025 financial results

Reuters
·
Nov 13, 2025

PAVmed Inc - Qtrly Shr Loss $0.29

THOMSON REUTERS
·
Nov 13, 2025

PAVmed Inc. to Report Third Quarter 2025 Financial Results

Reuters
·
Oct 30, 2025

PAVmed Inc. Announces Date for Upcoming Special Stockholders Meeting

Reuters
·
Oct 21, 2025

Lucid Diagnostics Inc. Files Initial Beneficial Ownership Statement for Director John R. Palumbo

Reuters
·
Oct 08, 2025

PAVmed Subsidiary Veris Health Launches Commercial Phase of Strategic Partnership with Ohio State University Comprehensive Cancer Center

Reuters
·
Oct 07, 2025

PAVmed Subsidiary, Veris Health and the Ohio State University Comprehensive Cancer Center Launch Commercial Phase of Strategic Partnership Agreement

THOMSON REUTERS
·
Oct 07, 2025